Concise review: Cancer cells escape from oncogene addiction: Understanding the mechanisms behind treatment failure for more effective targeting

Stem Cells

Volumn 32, Issue 6, 2014, Pages 1373-1379

  Pellicano, Francesca ^a   Mukherjee, Leena ^a   Holyoake, Tessa L ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Adult stem cells; BCR ABL; Cancer cells; Chronic myeloid leukemia; Hemopoietic stem cells; Oncogene addiction; Tyrosine kinase inhibitors

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; B RAF KINASE; BCR ABL PROTEIN; BEVACIZUMAB; BOSUTINIB; CETUXIMAB; CRIZOTINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; JNU 7706621; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; NILOTINIB; NVP AST 487; OLAPARIB; ONCOPROTEIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PONATINIB; PRO 001; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

BREAST CANCER; CANCER CELL; CANCER MODEL; CANCER STEM CELL; CARCINOGENESIS; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; CUTANEOUS MELANOMA; DIMERIZATION; DRUG TREATMENT FAILURE; GENE MUTATION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER; TUMOR ESCAPE; NEOPLASMS; PATHOLOGY; TREATMENT FAILURE;

HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; ONCOGENES; TREATMENT FAILURE;

EID: 84901471963     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1678     Document Type: Review

References (64)

1. Weinstein IB, Joe A,. Oncogene addiction. Cancer Res 2008; 68: 3077-3080.
2. Weinstein IB,. Disorders in cell circuitry during multistage carcinogenesis: The role of homeostasis. Carcinogenesis 2000; 21: 857-864.
3. Weinstein IB, Begemann M, Zhou P, et al. Disorders in cell circuitry associated with multistage carcinogenesis: Exploitable targets for cancer prevention and therapy. Clin Cancer Res 1997; 3 (pt 2): 2696-2702.
4. Torti D, Trusolino L,. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: Promises and perils. EMBO Mol Med 2011; 3: 623-636.
5. Heinrich MC, Corless CL, Demetri G D, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349.
6. Din OS, Woll PJ,. Treatment of gastrointestinal stromal tumor: Focus on imatinib mesylate. Ther Clin Risk Manag 2008; 4: 149-162.
7. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
8. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
9. Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480: 387-390.
10. Valabrega G, Montemurro F, Aglietta M, Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18: 977-984.
11. Sequist LV, Lynch TJ,. EGFR tyrosine kinase inhibitors in lung cancer: An evolving story. Annu Rev Med 2008; 59: 429-442.
12. Pao W, Chmielecki J,. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10: 760-774.
13. Yasuda H, Kobayashi S, Costa DB,. EGFR exon 20 insertion mutations in non-small-cell lung cancer: Preclinical data and clinical implications. Lancet Oncol 2012; 13: e23-31.
14. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 1734-1739.
15. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
16. Lord CJ, Ashworth A,. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008; 8: 363-369.
17. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
18. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-214.
19. Sharma SV, Settleman J,. Oncogene addiction: Setting the stage for molecularly targeted cancer therapy. Genes Dev 2007; 21: 3214-3231.
20. Bixby D, Talpaz M,. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011; 25: 7-22.
21. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-4707.
22. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325.
23. Konig H, Holtz M, Modi H, et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008; 22: 748-755.
24. Jorgensen HG, Allan EK, Jordanides NE, et al. Nilotinib exerts equipotent anti-proliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007; 109: 4016-4019.
25. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532-4539.
26. Konig H, Copland M, Chu S, et al. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 2008; 68: 9624-9633.
27. Konig H, Holyoake TL, Bhatia R,. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008; 111: 2329-2338.
28. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820.
29. Ren R,. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172-183.
30. Daley GQ, Van Etten RA, Baltimore D,. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
31. Huettner CS, Zhang P, Van Etten RA, et al. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000; 24: 57-60.
32. Koschmieder S, Gottgens B, Zhang P, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 2005; 105: 324-334.
33. Schemionek M, Elling C, Steidl U, et al. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 2010; 115: 3185-3195.
34. Perez-Caro M, Cobaleda C, Gonzalez-Herrero I, et al. Cancer induction by restriction of oncogene expression to the stem cell compartment. Embo J 2009; 28: 8-20.
35. Hamilton A, Helgason GV, Schemionek M, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2011; 119: 1501-1510.
36. Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396-409.
37. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
38. Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistency in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011; 118: 3657-3660.
39. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432.
40. Merante S, Orlandi E, Bernasconi P, et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005; 90: 979-981.
41. Mauro MJ, Druker BJ, Maziarz RT, Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res, 2004; 28 (suppl 1): S71-S73.
42. Su Chu AL, McDonald T, Snyder DS, Stephen JF, Ravi B,. Persistence of Leukemia Stem Cells in Chronic Myelogenous Leukemia Patients in Complete Cytogenetic Remission on Imatinib Treatment for 5 Years. Blood 2011; 118: 5565-5572.
43. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035.
44. Koptyra M, Falinski R, Nowicki MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108: 319-327.
45. Jiang X, Saw KM, Eaves A, et al. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007; 99: 680-693.
46. Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676-680.
47. Pellicano F, Holyoake TL,. Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks. J Exp Med 2011; 208: 2155-2158.
48. Hurtz C, Hatzi K, Cerchietti L, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 2011; 208: 2163-2174.
49. Zhang X, Ren R,. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia. Blood 1998; 92: 3829-3840.
50. Gross A W, Zhang X, Ren R,. Bcr-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol Cell Biol 1999; 19: 6918-6928.
51. Johnson KJ, Griswold IJ, O'Hare T, et al. A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice. PLoS One 2009; 4: e7439.
52. Chen M, Gallipoli P, DeGeer D, et al. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J Natl Cancer Inst 2013; 105: 405-423.
53. Chen Y, Hu Y, Zhang H, et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 2009; 41: 783-792.
54. Neviani P, Harb JG, Oaks JJ, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013; 123: 4144-4157.
55. Pellicano F, Copland M, Jorgensen HG, et al. BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta. Blood 2009; 114: 4186-4196.
56. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8: 355-368.
57. Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008; 453: 1072-1078.
58. Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119: 1109-1123.
59. Kumari A, Brendel C, Hochhaus A, et al. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 2012; 119: 530-539.
60. Machova Polakova K, Koblihova J, Stopka T,. Role of epigenetics in chronic myeloid leukemia. Curr Hematol Malig Rep 2013; 8: 28-36.
61. Grossmann V, Kohlmann A, Zenger M, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 2011; 25: 557-560.
62. Ashton JM, Balys M, Neering SJ, et al. Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell 2012; 11: 359-372.
63. McMurray HR, Sampson ER, Compitello G, et al. Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature 2008; 453: 1112-1116.
64. Gillies RJ, Verduzco D, Gatenby RA,. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012; 12: 487-493.